Dr. Jeffrey Bednarski, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Acute Myeloid Leukemia
Studies Childhood Leukemia
6 reported clinical trials
13 drugs studied
Affiliated Hospitals
Clinical Trials Jeffrey Bednarski, M.D., Ph.D. is currently running
Memory-like NK Cell Therapy
for Acute Myeloid Leukemia
Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant (allo-HCT). However, the complete remission (CR) rates and long term survival remain very poor in these patients and, therefore, there is an unmet need to develop more effective treatment approaches in patients who relapse after allo-HCT. Based on the initial promising results with our ongoing cytokine-induced memory-like (CIML) natural killer (NK) cell trial, the investigators hypothesize that combining the CIML NK cells with DLI approach will significantly enhance the graft versus leukemia and therefore potentially provide potentially curative therapy for these patients with otherwise extremely poor prognosis. Combining CIML NK cells with the DLI platform will also potentially allow these adoptively transferred cells to persist for longer duration as they should not be rejected by donor T cells as the CIML NK cells are derived from the same donor. The use of CIML NK cells is unlikely to lead to excessive graft versus host disease (GVHD) as previous studies have not been associated with excessive GVHD rates.
Recruiting1 award Phase 1 & 2
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Jeffrey Bednarski, M.D., Ph.D.
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jeffrey Bednarski, M.D., Ph.D. has experience with
- Fludarabine
- Ex Vivo T-cell Receptor Alpha-beta And CD19+ Depletion Using CliniMACs Plus
- Αβ-TCR/CD19 Cell Depleted Haploidentical Hematopoietic Stem Cell Graft
- Alemtuzumab
- Melphalan
- Thiotepa
Breakdown of trials Jeffrey Bednarski, M.D., Ph.D. has run
Acute Myeloid Leukemia
Childhood Leukemia
Severe Combined Immunodeficiency
Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey Bednarski, M.D., Ph.D. specialize in?
Jeffrey Bednarski, M.D., Ph.D. focuses on Acute Myeloid Leukemia and Childhood Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved Stage IV patients, or patients who are undergoing treatment.
Is Jeffrey Bednarski, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Jeffrey Bednarski, M.D., Ph.D. is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey Bednarski, M.D., Ph.D. has studied deeply?
Yes, Jeffrey Bednarski, M.D., Ph.D. has studied treatments such as Fludarabine, Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus, αβ-TCR/CD19 cell depleted haploidentical hematopoietic stem cell graft.
What is the best way to schedule an appointment with Jeffrey Bednarski, M.D., Ph.D.?
Apply for one of the trials that Jeffrey Bednarski, M.D., Ph.D. is conducting.
What is the office address of Jeffrey Bednarski, M.D., Ph.D.?
The office of Jeffrey Bednarski, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.